Home LiteratureArticle Details
PMID: 9765404 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.

Journal of virology ·Vol. 72 ·No. 11 ·1998-11-00 ·Pages 8644-9

Pepperl S, Benninger-Döring G, Modrow S, Wolf H, Jilg W

Abstract

We analyzed the immediate-early transactivator Rta of Epstein-Barr virus (EBV) for its role as a target for specific cytotoxic T lymphocytes (CTL). Panels of overlapping peptides covering the entire amino acid sequence of Rta were synthesized and used to induce and analyze specific CTL responses in EBV-positive donors. Using peptide-pulsed target cells, we found nine different CTL epitopes that are distributed over the entire protein sequence. One epitope restricted by HLA-A24 could be mapped to the decameric sequence DYCNVLNKEF between amino acid positions 28 and 37 of the Rta protein. A second epitope could be assigned to the same region of Rta (residues 25 to 39) and was shown to be restricted by HLA-B18. Another, minimal epitope could be mapped to the nonameric sequence ATIGTAMYK between amino acid positions 134 and 142; this peptide was restricted by HLA-A11. Another four epitopes were proven to be restricted by HLA-A2, -A3, -B61, and -Cw4 and were located between Rta residues 225 and 239, 145 and 159, 529 and 543, and 393 and 407, respectively. For two other epitopes, only the location within the Rta protein is known so far (residues 121 to 135 and 441 to 455); their exact HLA restriction patterns have not yet been identified. Using target cells infected with recombinant vaccinia virus containing the gene for Rta, we showed that six of eight Rta-specific CTL lines recognized the corresponding peptides also after endogenous processing. These data suggest that Rta comprises an important target for EBV-specific cellular cytotoxicity. Together with recent findings of other immediate-early and early proteins also acting as CTL targets, they reveal the role of proteins of the lytic cycle in the immune recognition of EBV-infected cells.

MeSH Terms
Amino Acid Sequence Antigen Presentation Antigens, Viral/genetics,metabolism Cell Line Epitope Mapping Epitopes/genetics,metabolism Genes, Immediate-Early HLA Antigens/metabolism HLA-A Antigens/metabolism HLA-A11 Antigen HLA-A24 Antigen Herpesvirus 4, Human/genetics,immunology,metabolism Humans Immediate-Early Proteins/genetics,immunology,metabolism Molecular Sequence Data Protein Binding T-Lymphocytes, Cytotoxic/immunology Trans-Activators/genetics,immunology,metabolism Transcription Factors/genetics,immunology,metabolism Viral Proteins
Chemicals
Antigens, Viral BRLF1 protein, Human herpesvirus 4 Epitopes HLA Antigens HLA-A Antigens HLA-A11 Antigen HLA-A24 Antigen Immediate-Early Proteins Trans-Activators Transcription Factors Viral Proteins
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Pepperl S
Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg, D-93053 Regensburg, Germany.
Benninger-Döring G
Modrow S
Wolf H
Jilg W
References (47)
47 references, click to expand
  1. The role of Epstein-Barr virus in lymphomas of HIV-carriers.
    APMIS Suppl. 1989;8:58-61 PMID: 2544216
  2. Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA.
    J Exp Med. 1995 Jun 1;181(6):2085-95 PMID: 7760000
  3. An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3).
    J Exp Med. 1990 Jan 1;171(1):345-9 PMID: 1688611
  4. An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants.
    J Virol. 1990 Aug;64(8):3974-6 PMID: 1695259
  5. Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.
    J Virol. 1991 Feb;65(2):996-1001 PMID: 1846213
  6. Severe chronic active Epstein-Barr virus infection syndrome.
    Clin Microbiol Rev. 1991 Jan;4(1):129-35 PMID: 1848476
  7. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.
    Nature. 1991 May 23;351(6324):290-6 PMID: 1709722
  8. Human T-cell recognition of Epstein-Barr virus-induced replication antigen complexes.
    Int J Cancer. 1991 Nov 11;49(5):656-60 PMID: 1657795
  9. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
    J Virol. 1992 Jan;66(1):122-31 PMID: 1309242
  10. The specificity of recognition of a cytotoxic T lymphocyte epitope.
    Eur J Immunol. 1992 Jan;22(1):191-5 PMID: 1370414
  11. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
    J Exp Med. 1992 Jul 1;176(1):169-76 PMID: 1377222
  12. Immune surveillance against Epstein-Barr virus.
    Semin Immunol. 1992 Apr;4(2):97-104 PMID: 1377517
  13. Cytotoxic T lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides.
    J Immunol. 1992 Oct 1;149(7):2406-14 PMID: 1326579
  14. HLA class I nucleotide sequences, 1992.
    Immunogenetics. 1993;37(4):239-50 PMID: 8420833
  15. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.
    J Virol. 1993 Mar;67(3):1572-8 PMID: 7679748
  16. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    J Exp Med. 1995 Jun 1;181(6):2221-8 PMID: 7539044
  17. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
    Nature. 1995 Jun 22;375(6533):685-8 PMID: 7540727
  18. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus.
    J Virol. 1995 Aug;69(8):4872-9 PMID: 7609055
  19. Vaccinia virus serpins B13R and B22R do not inhibit antigen presentation to class I-restricted cytotoxic T lymphocytes.
    J Gen Virol. 1995 Sep;76 ( Pt 9):2393-8 PMID: 7561783
  20. Immune regulation in Epstein-Barr virus-associated diseases.
    Microbiol Rev. 1995 Sep;59(3):387-405 PMID: 7565411
  21. A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.
    J Virol. 1996 Apr;70(4):2394-402 PMID: 8642667
  22. Epstein-Barr virus and the B cell: that's all it takes.
    Trends Microbiol. 1996 May;4(5):204-8 PMID: 8727601
  23. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism.
    Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9194-9 PMID: 8799177
  24. Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus.
    J Virol. 1996 Dec;70(12):8858-64 PMID: 8971014
  25. Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lymphocytes during infectious mononucleosis and in the normal carrier state.
    Blood. 1997 Mar 1;89(5):1665-77 PMID: 9057649
  26. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    J Immunol. 1997 Apr 1;158(7):3325-34 PMID: 9120290
  27. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response.
    J Exp Med. 1997 May 5;185(9):1605-17 PMID: 9151898
  28. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders.
    J Clin Microbiol. 1997 Jun;35(6):1612-5 PMID: 9163497
  29. HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population.
    Science. 1993 Apr 2;260(5104):98-100 PMID: 7682013
  30. The CD8 coreceptor interaction with the alpha 3 domain of HLA class I is critical to the differentiation of human cytotoxic T-lymphocytes specific for HLA-A2 and HLA-Cw4.
    Hum Immunol. 1993 Mar;36(3):149-55 PMID: 8320133
  31. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.
    J Exp Med. 1993 Sep 1;178(3):879-87 PMID: 7688791
  32. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
    J Virol. 1993 Dec;67(12):7428-35 PMID: 7693972
  33. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells.
    Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12000-4 PMID: 8265660
  34. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.
    Cell. 1978 May;14(1):9-20 PMID: 667938
  35. In vitro expansion of Epstein-Barr virus-specific HLA-restricted cytotoxic T cells direct from the blood of infectious mononucleosis patients.
    Immunology. 1987 Dec;62(4):647-54 PMID: 2828228
  36. Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with beta 2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association.
    Eur J Immunol. 1988 May;18(5):801-10 PMID: 2967765
  37. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.
    J Exp Med. 1988 Oct 1;168(4):1211-24 PMID: 2459295
  38. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency.
    Proc Natl Acad Sci U S A. 1988 Nov;85(22):8693-6 PMID: 2847171
  39. Use of synthetic oligopeptides in identification and characterization of immunological functions in the amino acid sequence of the envelope protein of HIV-1.
    J Acquir Immune Defic Syndr. 1989;2(1):21-7 PMID: 2537398
  40. Allele-specific peptide ligand motifs of HLA-C molecules.
    Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12005-9 PMID: 8265661
  41. Different activation of Epstein-Barr virus immediate-early and early genes in Burkitt lymphoma cells and lymphoblastoid cell lines.
    J Virol. 1994 Feb;68(2):1200-3 PMID: 8289351
  42. Epstein-Barr virus strategy in normal and neoplastic B cells.
    Cell. 1994 Jun 17;77(6):791-3 PMID: 8004668
  43. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3.
    J Gen Virol. 1994 Sep;75 ( Pt 9):2489-93 PMID: 7521394
  44. Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing.
    Immunogenetics. 1994;40(4):306-8 PMID: 7521860
  45. Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7.
    Eur J Immunol. 1995 Jan;25(1):18-24 PMID: 7531143
  46. MHC ligands and peptide motifs: first listing.
    Immunogenetics. 1995;41(4):178-228 PMID: 7890324
  47. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia.
    N Engl J Med. 1989 Sep 21;321(12):784-9 PMID: 2671734
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1998-11-00
Pages
8644-9
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC110276
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com